{
  "symbol": "GNLX",
  "company_name": "Genelux Corp",
  "ir_website": "https://www.genelux.com/investors",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "News Releases",
          "url": "https://investors.genelux.com/news-events/news-releases",
          "content": "­\n\n[Skip to content](#lfg-main-content)\n\n[ ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web-TAGLINE4.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo_black.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ](https://www.genelux.com/)\n\n![Investors](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-07-handshake-iStock-973715182-1920x800-flip.jpg)\n\n# News Releases\n\nYear All Years20242023202220212020\n\nAll Years\n\n[Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates](/news-releases/news-release-details/genelux-corporation-reports-third-quarter-2024-financial-results)\n\nWESTLAKE VILLAGE, Calif. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, \n\nNovember 14, 2024 \n\n[PDF Version](/node/7816/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-reports-third-quarter-2024-financial-results)\n\n[Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference](/news-releases/news-release-details/genelux-corporation-participate-fireside-chat-guggenheim)\n\nWESTLAKE VILLAGE, Calif. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will discuss clinical-stage programs, recent announcements, and upcoming \n\nNovember 6, 2024 \n\n[PDF Version](/node/7801/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-participate-fireside-chat-guggenheim)\n\n[Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer](/news-releases/news-release-details/genelux-corporation-announces-first-patient-dosed-phase-2-trial)\n\n– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer – – Trial represents second indication in the clinic for Olvi-Vec via systemic \n\nOctober 22, 2024 \n\n[PDF Version](/node/7786/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-announces-first-patient-dosed-phase-2-trial)\n\n[Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit](/news-releases/news-release-details/genelux-corporation-participate-2024-maxim-healthcare-virtual)\n\nWESTLAKE VILLAGE, Calif. , Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the Board, will participate at the 2024 Maxim Healthcare Virtual Summit taking place \n\nOctober 9, 2024 \n\n[PDF Version](/node/7776/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-participate-2024-maxim-healthcare-virtual)\n\n[Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference](/news-releases/news-release-details/genelux-corporation-present-hc-wainwright-global-investment-0)\n\nWESTLAKE VILLAGE, Calif. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in \n\nSeptember 3, 2024 \n\n[PDF Version](/node/7726/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-present-hc-wainwright-global-investment-0)\n\n[Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates](/news-releases/news-release-details/genelux-corporation-reports-second-quarter-2024-financial)\n\nWESTLAKE VILLAGE, Calif. , Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. “The past quarter has continued to be \n\nAugust 14, 2024 \n\n[PDF Version](/node/7696/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-reports-second-quarter-2024-financial)\n\n[Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024](/news-releases/news-release-details/genelux-corporation-participate-fireside-chat-btigs-virtual-0)\n\nWESTLAKE VILLAGE, Calif. , July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman, will discuss clinical-stage programs, recent announcements, and upcoming milestones in \n\nJuly 30, 2024 \n\n[PDF Version](/node/7656/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-participate-fireside-chat-btigs-virtual-0)\n\n[Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants](/news-releases/news-release-details/genelux-corporation-announces-pricing-approximately-275-million)\n\nWESTLAKE VILLAGE, Calif. , May 24, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation ( Genelux ) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 \n\nMay 24, 2024 \n\n[PDF Version](/node/7536/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-announces-pricing-approximately-275-million)\n\n[Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants](/news-releases/news-release-details/genelux-corporation-announces-proposed-public-offering-common)\n\nWESTLAKE VILLAGE, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation ( Genelux ) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants. \n\nMay 23, 2024 \n\n[PDF Version](/node/7521/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-announces-proposed-public-offering-common)\n\n[Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates](/news-releases/news-release-details/genelux-corporation-reports-first-quarter-2024-financial-results)\n\nWESTLAKE VILLAGE, Calif. , May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates. “Our pivotal Phase 3 registration trial of Olvi-Vec \n\nMay 9, 2024 \n\n[PDF Version](/node/7506/pdf)\n\n[Read More](/news-releases/news-release-details/genelux-corporation-reports-first-quarter-2024-financial-results)\n\nDisplaying 1 - 10 of 36 \n\nWe use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.\n\n[Ok](#) [Privacy policy](https://genelux2022.mhwebstaging.com/privacy-policy/)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.genelux.com/financial-information/filings-disclosures",
          "content": "­\n\n[Skip to content](#lfg-main-content)\n\n[ ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web-TAGLINE4.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo_black.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ](https://www.genelux.com/)\n\n![Investors](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-07-handshake-iStock-973715182-1920x800-flip.jpg)\n\n# Filings & Disclosures\n\nGroup - Any -3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\n- Any -\n\nFiling year - Any -2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | Filing Group | View  \n---|---|---|---|---  \nNov 14, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001493152-24-045790) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings | [View HTML](/node/7821/html) [0001493152-24-045790.pdf](/static-files/5916a0eb-6e52-495a-92c1-33acebdcd09f) [0001493152-24-045790.rtf](/static-files/f0bf1505-7b66-4200-abf3-e1fb5d6ac5be) [0001493152-24-045790.xls](/static-files/58b8176f-5c6d-46fe-94d7-7d3d3d2af8f6) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001493152-24-045790)  \nNov 08, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001493152-24-044258) | Report of unscheduled material events or corporate event |  Current Reports | [View HTML](/node/7806/html) [0001493152-24-044258.pdf](/static-files/fd26af79-c917-426b-a7ae-2bfed270cded) [0001493152-24-044258.rtf](/static-files/07a9461d-678b-4418-8b8d-bd2839cc7c26) [0001493152-24-044258.xls](/static-files/431ecf85-7276-4fca-bfcc-88b069ed6748) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001493152-24-044258)  \nOct 25, 2024 | [SC 13G](/sec-filings/sec-filing/sc-13g/0000902664-24-005989) | A statement of beneficial ownership of common stock by certain persons |  Other | [View HTML](/node/7796/html) [0000902664-24-005989.pdf](/static-files/4339b629-d4dd-4965-a425-e2a71ef8a681) [0000902664-24-005989.rtf](/static-files/a7676451-692e-411f-bee1-4a4f9addbdee) [0000902664-24-005989.xls](/static-files/e11cf88d-c7f1-43ba-b3b0-c11e325c36e9)  \nOct 22, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001104659-24-110560) | An amendment to the SC 13G filing |  Other | [View HTML](/node/7791/html) [0001104659-24-110560.pdf](/static-files/05fabb00-a58d-4ccc-8828-d5292dfa6955) [0001104659-24-110560.rtf](/static-files/3c8a4df4-8e8b-4baa-953f-58ae3c648851) [0001104659-24-110560.xls](/static-files/d37ccc77-1c37-47cf-a892-643c418be1c4)  \nOct 21, 2024 | [4](/sec-filings/sec-filing/4/0001415889-24-025460) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/7781/html) [0001415889-24-025460.pdf](/static-files/40c162e0-3be2-4ed5-904e-32576e9f6fb6) [0001415889-24-025460.rtf](/static-files/5ef287fd-bbb5-40bc-a67e-034e96f23c83) [0001415889-24-025460.xls](/static-files/76b30592-33e5-4860-b26c-8f2e9bde14ca)  \nOct 03, 2024 | [8-K](/sec-filings/sec-filing/8-k/0001493152-24-039417) | Report of unscheduled material events or corporate event |  Current Reports | [View HTML](/node/7771/html) [0001493152-24-039417.pdf](/static-files/ec385b10-f21f-463e-9ad3-110c0994cd7a) [0001493152-24-039417.rtf](/static-files/26a53dc6-e642-4b0d-8f75-ad9d35a8630c) [0001493152-24-039417.xls](/static-files/7232d73a-d666-4a6d-a100-8ff2b3b636bf) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001493152-24-039417)  \nSep 26, 2024 | [4/A](/sec-filings/sec-filing/4a/0001415889-24-023999) | Amendment to a previously filed 4 |  3,4,5 | [View HTML](/node/7766/html) [0001415889-24-023999.pdf](/static-files/2e8676d4-69ad-41af-b19a-493ee65c2865) [0001415889-24-023999.rtf](/static-files/df13f5e8-be92-4d1b-8efa-7588178aa37d)  \nSep 13, 2024 | [4](/sec-filings/sec-filing/4/0001415889-24-023393) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/7761/html) [0001415889-24-023393.pdf](/static-files/ee4d3f05-3965-4139-be6b-db6a9d8c5ee4) [0001415889-24-023393.rtf](/static-files/24d5e48b-886c-472a-b4f9-e5f5ab1854b1) [0001415889-24-023393.xls](/static-files/eda9e6c9-505e-40c2-8c18-18f9c854cdaf)  \nSep 12, 2024 | [4](/sec-filings/sec-filing/4/0001415889-24-023335) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/7751/html) [0001415889-24-023335.pdf](/static-files/c75872b8-7e60-4593-b799-d58c10815dde) [0001415889-24-023335.rtf](/static-files/f38a261f-cdcb-497d-99c3-fdda9198f1fb) [0001415889-24-023335.xls](/static-files/8179b0c7-8152-42c4-87c9-4dc70d7dc6ff)  \nSep 11, 2024 | [144](/sec-filings/sec-filing/144/0001950047-24-006965) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other | [View HTML](/node/7741/html) [0001950047-24-006965.pdf](/static-files/471b3646-927a-4282-abde-ab21532dcda2) [0001950047-24-006965.rtf](/static-files/7181d696-cc8b-43db-8111-e326514217ec)  \n  \nDisplaying 1 - 10 of 239 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\nWe use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.\n\n[Ok](#) [Privacy policy](https://genelux2022.mhwebstaging.com/privacy-policy/)\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": []
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Events & Presentations",
          "url": "https://investors.genelux.com/news-events/events-presentations",
          "content": "­\n\n[Skip to content](#lfg-main-content)\n\n[ ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web-TAGLINE4.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/bridge-img-logo_black.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ![Logo](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-05-GENELUX-Logo-RGB-Web.png) ](https://www.genelux.com/)\n\n![Investors](/sites/g/files/knoqqb78316/themes/site/nir_pid7846/dist/images/2021-07-handshake-iStock-973715182-1920x800-flip.jpg)\n\n# Events & Presentations\n\n##  Presentations \n\n[Genelux Corporate Presentation - November ](/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118)\n\n[2024 Genelux Annual Stockholder Meeting Corporate Presentation](https://www.youtube.com/watch?v=KpxoMYgi1Cw)\n\n##  Upcoming Events \n\nThere are no upcoming events available at this time. \n\n##  Past Events \n\n[Guggenheim Inaugural Healthcare Innovation Conference Fireside Chat](/events/event-details/guggenheim-inaugural-healthcare-innovation-conference-fireside-chat)\n\nNov 11, 2024 at 1:30 PM EST \n\n[Webcast Replay](https://wsw.com/webcast/guggen/register.aspx?conf=guggen&page=gnlx&url=https%3A//wsw.com/webcast/guggen/gnlx/1958805)\n\n[H.C. Wainwright Global Investment Conference Fireside Chat ](/events/event-details/hc-wainwright-global-investment-conference-fireside-chat)\n\nSep 11, 2024 \n\n[Webcast Replay](https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0)\n\nWe use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.\n\n[Ok](#) [Privacy policy](https://genelux2022.mhwebstaging.com/privacy-policy/)\n"
        }
      ]
    }
  ]
}